SEC Form 4 · accession 0001189394-26-000005
Caris Life Sciences, Inc. · CAI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jon Halbert
Director
Period of report
May 15, 2026
Accepted (ET)
Jul 13, 2026 · 7:06 am EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0002019410
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3,F4 | May 15, 2026 | P | 68,000 | $14.56 | A | 704,598 | I | By LAH Investments, Ltd. |
| Common Stock | holding | — | — | — | 118,621 | D | ||
| Common StockF1 | holding | — | — | — | 637,887 | I | By Family Trust |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Includes an aggregate of 23,196 shares received in pro rata distributions exempt pursuant to Rule 16a-9.
- F2The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.49 to $14.60 inclusive. The reporting person undertakes to provide to Caris Life Sciences, Inc., any security holder of Caris Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- F3Includes an aggregate of 11,598 shares received in pro rata distributions exempt pursuant to Rule 16a-9.
- F4The Reporting Person disclaims beneficial ownership except to the extent of his pecuniary interest therein.